Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $698.58M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 3.99M
Average 2.47M
Returns on capital
Prime Medicine, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-166.4%
avg -106.1%
ROIC
-66.5%
avg -72.7%
ROA
-58.7%
avg -50.1%
Analysis
ROA is currently the strongest return metric at -58.7% versus its period average of -50.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Allan Reine | Chief Executive Officer & Director | USD 1.07M | 51 | 1.30M | 0.72% |
Svetlana Makhni | Chief Financial Officer | USD 924.03K | 42 | — | — |
Ann L. Lee | Chief Technical Officer | USD 760.04K | 64 | 375.00K | 0.21% |
Matthew J. Hawryluk | Chief Business Officer | USD 680.8K | 47 | — | — |
Jeffrey D. Marrazzo | Executive Chair | USD 140.16K | 47 | 75.00K | 0.04% |
Andrew Anzalone | Co-Founder & Head of Platform | — | 39 | — | — |
David R. Liu | Co-Founder & Member of Scientific Advisory Board | — | — | 20.24M | 11.21% |
Mohammed Asmal | Chief Medical Officer | — | — | — | — |
Ryan E. Brown | Chief Legal Officer | — | 47 | — | — |
Niamh Alix | Chief Human Resources Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +87.0% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +87.0% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Prime Medicine, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about PRME's management, answered from reported figures.
Who manages PRME?
Prime Medicine, Inc. (PRME) lists 10 active executives. The top listed executive is Allan Reine, Chief Executive Officer & Director.
Are PRME insiders buying or selling?
Recent insider activity shows net buying of $121.31M.
Continue the stock analysis
Jump to another research area for this company.